The African psychoactive alkaloid Ibogaine, Schedule 1 in the USA, researched for substance use since the 1950’s, has demonstrated effectiveness in reversing tolerance & craving for opioids, stimulants & alcohol. Risks & fatalities are involved, due to the demographic, screening, inducing bradycardia, prolonging the QT interval & blocking the Potassium hERG channel, further complicated by opioid maintenance medications & psychiatric drugs. Almost all ibogaine centres, rapidly increasing in ...